Exhibit 12.1

ARIAD Pharmaceuticals, Inc.
Computation of Deficiency of Earnings to Fixed Charges
($ in thousands)

																Nine Months
																Ended
	Year Ended December 31,															September 30,
	2001			2002			2003			2004			2005			2006
Earnings (loss):
Pretax income from continuing operations	$	(19,759	)	$	(27,843	)	$	(19,726	)	$	(35,573	)	$	(55,482	)	$	(47,574	)
Fixed charges (from below)		395			438			426			395			587			461
Amortization of capitalized interest		0			0			0			0			14			13
Interest capitalized		0			0			0			0			(42	)		0
Total earnings (loss)	$	(19,364	)	$	(27,405	)	$	(19,300	)	$	(35,178	)	$	(54,923	)	$	(47,100	)
Fixed charges:
Interest expensed	$	285		$	323		$	303		$	272		$	422		$	369
Interest capitalized		0			0			0			0			42			0
Estimated interest portion of rent expenses		110			115			123			123			123			92
	$	395		$	438		$	426		$	395		$	587		$	461
Coverage deficiency	$	19,759		$	27,843		$	19,726		$	35,573		$	55,510		$	47,561